Diagnostics Company SIRS-Lab insolvent

Investor search for Molecular Diagnostics Company started

14-Jan-2013 - Germany

SIRS-Lab requested the opening of insolvency proceedings. The company, founded ten years ago, develops molecular diagnostic technologies for life-threatening infections as sepsis, also known as blood poisoning. Sepsis claims 250.000 victims per year in the USA alone. Therefore SIRS-Lab has developed a new diagnostic system.

At the end of December, SIRS-Lab requested the opening of insolvency proceedings because the public and private shareholders could not agree upon a further funding.

“SIRS-Lab has developed an innovative diagnostic technology for sepsis, also known as blood poisoning. At the end of last year, a current clinical study about the efficiency of the new pathogen test could successfully be finished. In order to bring the test on the market, further investment, on which the current shareholders cannot agree upon, is necessary. At short notice, we therefore are searching for investors for this very interesting diagnostics company. The first meetings with management and employees made me very confident to proceed with the company. The salaries of the 30 SIRS-Lab employees are currently secured through the insolvency compensation payment,“ comments Prof. Rolf Rattunde from Leonhardt Rechtsanwälte Erfurt.

Other news from the department business & finance

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics